{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004455","form_type":"8-K","ticker":null,"cik":"0001496323","company_name":"IGM Biosciences, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.781029+00:00","generated_at":"2026-05-28T04:50:36.768531+00:00","sec_items":["2.02","7.01","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IGM Biosciences halts two autoimmune programs, slashes workforce 73%","bullets":["Halted imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) trials due to insufficient B cell depletion in Phase 1b.","Workforce reduction of 73% to preserve cash; cash and investments $183.8M as of Dec 31, 2024.","Evaluating internal options and strategic alternatives to maximize shareholder value.","CEO Mary Beth Harler stated interim data did not meet high bar for success."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004455","json":"https://secwatch.observer/filing/0001193125-25-004455.json","markdown":"https://secwatch.observer/filing/0001193125-25-004455.md","text":"https://secwatch.observer/filing/0001193125-25-004455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/0001193125-25-004455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/d778635d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:50:36.768531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0595f43c894c3d7ea09b4baad8d6162c144138b2","claim":"IGM Biosciences, Inc. announced a restructuring affecting autoimmune disease pipeline (imvotamab and IGM-2644 programs) (approximately 73% reduction in force).","evidence_excerpt":"On January 9, 2025, IGM Biosciences, Inc. (the “Company”) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases (the “2025 Restructuring”). As part of the 2025 Restructuring, which was approved by the Company’s Board of Directors on January 7, 2025, the Company is taking steps, including an approximately 73% reduction in force, to preserve cash.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/0001193125-25-004455-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Affected area","value":"autoimmune disease pipeline (imvotamab and IGM-2644 programs)"},{"label":"Headcount","value":"approximately 73% reduction in force"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}